IMMX vs IMVT: fair value comparison
Immix Biopharma, Inc. and Immunovant, Inc. · Updated 2026-10-19
IMMX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. IMVT has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, IMMX currently ranks higher by quality score.
| IMMX | IMVT | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $7.98 | $26.73 |
| 12-month range | $3.03–$14.47 | $18.74–$44.96 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #241 of 301 Healthcare | #243 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | — |
| RSI zone | Oversold | Oversold |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The lower-middle quarter | The lower-middle quarter |
Full single-stock breakdowns: IMMX fair value analysis · IMVT fair value analysis